ABSTRACT
INTRODUCTION
Although perhaps the most easily approached somatic tissue, the skin has proven to be a challenging site for efforts to achieve therapeutic gene delivery (14, 23) . In addition to transience of therapeutic gene expression, important challenges have included an inability to reliably target gene expression to all cells within a given skin-tissue compartment. Such high-efficiency gene transfer can be defined as achieving therapeutic transgene delivery to a high percentage of cells within a given population. It may be absolutely essential to correction of disorders in which disease pathology could be perpetuated by the persistence of significant numbers of uncorrected cells within the tissue. Such inefficient gene transfer, for example, might fail to prevent development of malignancies in xeroderma pigmentosum, where the existence of a residual subset of epidermal cells with defective DNA repair would serve as an effective target for initiating and promoting neoplastic effects of UV irradiation. Therapeutic gene transfer efforts to the skin are still at the model stage, and achieving the capability for highefficiency cutaneous gene transfer may be an important step before the initiation of human trials for a specific subset of disorders.
Most cutaneous gene delivery efforts fall into two major categories: ( i ) direct administration of vectors to intact skin by approaches such as direct injection, topical application and particle bombardment or ( ii ) grafting of cells after gene transfer in tissue culture to regenerate genetically engineered skin tissue. To date, direct administration efforts have been characterized by a low efficiency of gene transfer, with only a minority of cells within the epidermis or dermis expressing the delivered gene (2, 13, 17) . In contrast, the latter approach involving grafting of genetically modified cells can achieve gene expression in virtually all cells within regenerated skin tissue. This has been most evident in human epidermis regenerated after retroviral gene transfer in vitro (3, 5, 10) .
The initial success of retrovirusbased cutaneous gene delivery efforts in producing skin tissue in which virtually all cells express the desired transgene (3, 5, 10) does not necessarily mean this approach can now be widely applied in gene therapy model efforts. The reason for this is that not all retroviral vectors can be produced at high enough titers to be comparable to those used in the studies noted above and in prior initial landmark efforts in vitro (12) . Several factors may prevent production of vectors at titers high enough to be effective in previous approaches. First, retroviral vectors incorporating therapeutic transgenes for the treatment of human genetic skin disorders may contain large cDNA inserts and therefore lowered viral titers that are incapable of achieving high-efficiency gene transfer to keratinocytes grown in vitro. In addition, even smaller inserts well within the 5-7-kb carrying capacity of retroviral vectors can lower retroviral titer in ways that are poorly understood.
Among the important elements influencing the efficiency of retroviral gene transfer are: ( i ) the titer of the retroviral vector preparation, defined as the number of infectious particles per milliliter ( ii ) the efficiency of viral binding and infection of target cells and ( iii ) the cell division status of the targetcell population. An optimization of the second and third components may help to boost gene-transfer efficiencies in the case of lower titer vectors.
In addition to enhancing the efficiency of initial gene transfer, drug-selection can be used after low-efficiency gene transfer to generate a population composed of only those cells that have been productively transduced with the retroviral vector. This requires incorporation of appropriate drug-resistance markers into the vector. Neomycin resistance, in spite of suggestions that it may exert unwanted effects on keratinocyte proliferation and differentiation, has been most widely used in keratinocytes to date (9, 22) . Although such drug selection is attractive in that it can accomplish the goal of achieving entirely engineered cell populations even after relatively low initial efficiencies of gene transfer, such a process can be traumatic to primary cells. An optimal selective agent for use with keratinocytes has not yet been characterized.
To improve the ability to produce populations of early passage human keratinocytes that are entirely genetically engineered before grafting, we have developed an approach that boosts the efficiency of retroviral transduction using packaging cell-free viral preparations. We have also used internal ribosome entry site (IRES) sequences to co-express drug-resistance genes and identified blasticidin as a promising agent for use with human keratinocytes. Together, these advances bring the capacity for high-efficiency gene transfer within reach for a wide array of retroviral vectors being developed for human cutaneous gene transfer.
MATERIALS AND METHODS

Vector Production
Retroviral expression vectors were constructed using the LZRS backbone vector (15 (4, 15) . Viral supernatant was passed through 0.22-µ m filters before storage at -80°C. Titer was determined as described (15) .
Gene Transfer and Pharmacologic Selection
Primary human keratinocytes were isolated (20) and plated at a density of 5 × 10 4 per 35-mm well and incubated in SFM/154(1:1) for 12-24 h. Cells were pre-incubated in 2 mL of a 1:1 mixture of serum-free media (SFM) (Life Technologies, Gaithersburg, MD, USA) and media 154 (Cascade Biologics, Portland, OR, USA) with 5 µ g/mL polybrene for 5 min, followed by addition of 2 mL thawed viral supernatant supplemented to 5 µ g/mL polybrene. Plates were centrifuged at 300 × gfor 1 h at 32°C. Medium was then aspirated from wells, after which 3 mL fresh SFM/154 were added. Incubation was continued at 37°C for 2 days, followed by 5-bromo-4-chloro-3-indolyl-β -D -galoctop yranoside (X-gal) staining or, in the case of pharmacologic selection, followed by trypsinization and replating at 5 × 10 4 per 35-mm well. At day 3, selective agent was added to half the replicate transductions. At daily intervals thereafter, media were aspirated and replaced with fresh media containing selective agent. Parallel transduced cultures were subjected to X-gal staining at day 3 before the addition of selective agents and at day 10 after 7 days of selection. Selective agents included 100 µ g/mL geneticin (Life Technologies), 200 µ g/mL hygromycin (Sigma Chemical, St. Louis, MO, USA) and 5 µ g/mL blasticidin (Calbiochem-Novabiochem, La Jolla, CA, USA); these optimal concentrations were selected after titration studies to achieve efficient killing of untransduced cells. For analysis of gene-transfer efficiency, 3 separate low-power fields were counted for each transduction; the number of Xgal-positive cells were divided by the total number of cells present in the field to determine the percentage of genetransfer efficiency.
Production of Genetically Engineered Human Epidermis In Vivo
Genetically engineered epidermis was regenerated on nude mice as previously described (5, 18) .
Analysis of Gene Expression
For immunofluorescence, frozen skin tissue sections were fixed, in acetone for 15 min, incubated with rabbit anti-β -gal antibodies (5 Prime->3 Prime, Boulder, CO, USA) at a dilution of 1:100 for 30 min, followed by fluorescein isothiocyanate (FITC)-conjugated, goat-anti-rabbit-Ig antibodies (Sigma Chemical) at a dilution of 1:200 for 30 min. Washing with 3 changes of phosphate-buffered saline (PBS) for 30 min was performed between each step.
RESULTS AND DISCUSSION
Effects of Gene Transduction Conditions on the Efficiency of Gene Transfer to Early Passage Human Keratinocytes
We examined variables influencing retroviral gene transfer efficiency in primary keratinocytes from human skin. First, we examined transduction conditions such as temperature, polybrene concentration and centrifugation. Our reference lacZ retroviral expression vector at a titer of 5 × 10 5 /mL is capable of 20%-40% gene-transfer efficiency to primary keratinocytes using current protocols (12, 15) . Using this viral preparation, we examined the impact of transduction conditions in increasing gene-transfer efficiency to these cells. Low-speed centrifugation (300 × g ) for 1 h during incubation with retroviral supernatant augmented genetransfer efficiency 1.3-fold, as measured by X-gal staining (Figure 1a) . Room temperature centrifugation was less consistently productive of efficient gene transfer than that carried out at a constant temperature of 3 2°C; the latter showed a 1.25-fold improvement (Figure 1a) . Addition of polybrene increased the efficiency, with up to 6-fold increase in gene transfer at the concentration of 5 µ g/mL in retroviral supernatant; however, levels greater than 10 µ g/mL were associated with abnormalities in cell morphology and decreased efficiency of gene transfer. Upon combining low-speed centrifugation at 32°C with optimized polybrene concentration, a lacZ vector at 5 × 10 5 /mL produced 99.5% ± 0.5% gene-transfer efficiency, as determined by cell counting of 5 independent transductions (Figure 1c) .
Generation of Retroviral Vectors for Rapid Production of Entirely Engineered Primary Cell Populations
Vectors containing altered promoters or large inserts can demonstrate lowered titers, which lead to inadequate levels of gene transfer. To maximize gene-transfer efficiency with such vectors, we have used IRES sequences from EMCV. IRES sequences are 435-610-bp sequences isolated from several different viruses that allow multiple proteins to be translated from a single mRNA (1, 21) . We produced a series of retroviral vectors containing the E. coli lacZgene followed by an ECMV-IRES sequence then a drug-resistance marker; the design of these vectors is diagrammed in Figure 2a , along with the initial approach to evaluate their efficacy (Figure 2b ). LacZ-IRES, drug-resistance vectors for hygromycin and blasticidin resistance allowed production of >99% β -galactosidase ( β -gal)-positive cells after 7 days of drug selection from plates of cells <30% β -gal-positive on day 3 ( Figure 2, c and d) . All colonies generated after hygromycin and blasticidin selection stained blue, suggesting a very high efficiency of gene transfer to clonal progenitor cells; whereas, neomycin-selected colonies showed variable staining ranging from 0%-100% positive cells per colony. In the case of these neomycin-based constructs, a high percentage of cell clusters lacked β -gal expression, and drug selection appeared to trigger morphologic changes suggestive of differentiation. The latter effect is consistent with previously reported results in canine cells (22) . These gene delivery vectors allowing rapid pharmacologic selection may be valuable in producing uniformly engineered early-passage keratinocyte populations at lower titers of vector.
Production of Engineered Human Skin In Vivo after Rapid Pharmacologic Selection
To be useful in cutaneous gene transfer efforts, engineered cell populations produced by rapid pharmacologic selection after transduction in vitro must be capable of regenerating normal human skin elements in vivo. In the case of keratinocytes, extensive grafting experience has been gained in humans (6, 11, 16) , and we used recently refined methods (5, 18) to regenerate skin on immune-deficient mice from primary human keratinocytes after 7 days of selection with blasticidin. Blasticidin-selected cells regenerated clinically normal epidermis that displayed normal tissue architecture in vivo upon analysis 4 weeks after grafting ( Figure  3, a and b) . As we and others have previously demonstrated in this grafting model (3, 18) , immunostaining with species-specific antibodies to bullous pemphigoid-180 antigen (BPAG2) (8) and involucrin (19) demonstrated a normal pattern of gene expression for these proteins specific to the basal and suprabasal epidermis, respectively (data not shown). As expected, the entire engineered epidermis demonstrated lacZ expression, while the nonengineered epidermis did not (Figure 3, c-e) , indicating that gene expression can be achieved throughout epidermis regenerated from keratinocytes subjected to rapid drug selection in vitro.
Here, we have refined approaches to high-efficiency gene transfer to primary human cells using cell-free vector preparations at titers within the range of most retroviral vehicles being developed for cutaneous gene therapy. The ability to rapidly effect gene transfer at high efficiency to primary skin cells may circumvent unwanted differentiation and senescence associated with long-term growth and selection in vitro (22) . Our new (target-gene)-IRES-(drug-resistance) vectors, namely LZEH and LZEB, allowed for rapid pharmacologic selection of primary keratinocytes. Our findings underscore the fact that not all selective agents function with equal efficacy. Although reported effective with canine keratinocytes in a prior study, histidinol was not a focus of the current work because initial efforts with this agent failed to demonstrate efficient selection of human keratinocytes (R. Freiberg and P.A. Khavari, unpublished) . The ability to achieve efficient gene deliv -ery in epidermis, both through enhanced gene-transfer efficiency with lower-titer vectors and effective selection of genetically engineered cells, is an important capability in the initiation of cutaneous gene-transfer efforts in humans. Combined with vector elements recently shown to permit sustained gene expression in vivo in human skin (7), this capability for efficient epidermal gene delivery can be applied in efforts at lasting genetic correction of disorders such as genetic skin disease.
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